Finance Outlook India’s Post

Biotech funding is the financial backing of biotechnology research and development, usually through private investors or venture capital firms. Some notable biotech funding deals in recent months include ¹: - Recent biotech pre-seed funding: - NXI Therapeutics (Switzerland): $3.96 million, for immunotherapies - Recent biotech seed funding: - Advesya (France): $23 million, for cancer therapies - Cumulus Oncology (United Kingdom): $11.45 million, for cancer drug discovery - DISCO Pharmaceuticals (Germany): $21.75 million, for drug discovery - Recent biotech series A funding: - Claris Bio (United States): $57 million, for corneal therapies - Resalis Therapeutics (Italy): $10.95 million, for non-coded RNA-based therapeutics - OnCusp Therapeutics (United States): $100 million, for oncology assets - Recent biotech series B funding: - Vico Therapeutics (Netherlands): $60 million, for RNA modulation - Full-Life Technologies (China, Belgium): $47.3 million, for radionuclide drug conjugates - Avistone Biotechnology (China): $140 million, for targeted cancer drugs #biotech #funding #venturecapital #investing #biotechnology #lifesciences #healthcare #innovation #startups #biotechnews #pharmaceuticals #medtech #biotechindustry #investmentnews #fundingnews #biotechcompanies #biotechinvesting

It’s time to find out who bagged the biggest private biotech investments in June 2024! 💰 The biggest funding rounds went to the companies Formation Bio, ITM Isotope Technologies Munich SE, and Marea Therapeutics. 📈 Meanwhile, around the world, oncology and central nervous system players attracted the biggest funding rounds overall. 🌍 Read our latest article to find out more about biotech’s biggest private investments in June, as we break down the investments by location and funding type, and compare June’s fundraising to previous months. 💡 https://lnkd.in/dYvuBVt9 #biotechinvestments #oncologyresearch #biotechfunding #healthcareinnovation #investmenttrends #globalbiotech #lifesciences Santa Ana Bio, Inc. | Alzheon, Inc. | Preserving Future Memories | Bright Peak Therapeutics | iOnctura | InduPro | Exsilio Therapeutics | Elion Therapeutics | Enveda Biosciences | Iambic Therapeutics | Spur Therapeutics | āshibio, Inc | Adcytherix | Envisagenics | Vilya | Frontier Medicines | Augustine Therapeutics | GPN Vaccines

UNP Scores $32M for AI-Powered Macrocycle Therapeutics - HIT Consultant #UNP Scores $32M for AI-Powered Macrocycle Therapeutics #Summary: UNP, a healthcare technology company, has raised $32 million in funding for its AI-powered macrocycle therapeutics. The company aims to develop novel treatments for diseases that are currently difficult to treat. The funding will be used to advance the company's drug discovery platform and accelerate the development of its pipeline. UNP's technology combines artificial intelligence and machine learning to design and optimize macrocycles, which are large, complex molecules that can interact with disease targets. The company's approach has the potential to revolutionize drug discovery and lead to the development of more effective therapies. #Introduction: UNP, a healthcare technology company, has secured $32 million in funding ai.mediformatica.com #platform #funding #oncology #biotech #design #globalhealth #health #healthinnovation #innovation #medical #merckglobalhealthinnovationfund #seriesa #digitalhealth #healthit #healthtech #healthcaretechnology @MediFormatica (https://buff.ly/3tp5PyH)

Do you want to learn more about some of the top biotech companies based in Denmark? 🇩🇰 In recent years, Denmark’s life sciences sector has accelerated its output of high-quality research, as the country was ranked 16th overall for biological sciences-related output in 2022. 🚀 It is also among the fastest-growing nations in Europe for biotech investment, hitting $434 million in 2021. 💰 Check out our latest article as we take a look at 9 biotech companies in Denmark leading innovation in the sector. 👇️ https://lnkd.in/dfcA8RCn #biotechindenmark #lifesciences #innovation #biotechinvestment #danishbiotech #researchanddevelopment #biotechcompanies #bioinnovation Acesion Pharma | Adcendo | Ascendis Pharma | Bavarian Nordic | Genmab | Hoba Therapeutics | IO Biotech | Minervax ApS | Zealand Pharma

#fundingalert 💼Company: HEPHAISTOS-Pharma 💰Funding: €4.5 Million ⚡Round: Seed 👥Investors: Elaia, xista science ventures, the Fondation Fournier-Majoie and Noshaq. HEPHAISTOS-Pharma is a preclinical biotech company developing the next generation of #immunostimulants against cancer, revolutionizing immune stimulation targeting innate immunity with a unique technology for intravenous administration, opening the way to metastatic and hard-to-treat indications. This seed round will mainly #finance the industrialization of drug production and regulatory toxicity studies to file for the CTA in Europe. HEPHAISTOS already has a lot of preclinical data in many cancer indications, but they plan to generate new additional data in monotherapy against unmet medical needs and in combination with promising drugs from other pharmaceutical companies. Frederic CAROFF, Florian Denis, Martine Caroff, Alexey Novikov Read more - https://lnkd.in/gYkPH4mH To share your startup story write us on - contact@startuprise.co.uk #HEPHAISTOSPharma #biotechstartup #revolutionizing #monotherapy #pharmaceutical #funding #fundingnews #news #startup #startupnews #startuprise

🔵🔴⚪𝗖𝗲𝗹𝗹 𝘁𝗵𝗲𝗿𝗮𝗽𝘆 𝘄𝗶𝘁𝗵𝗼𝘂𝘁 𝗰𝗲𝗹𝗹𝘀': 𝗖𝗮𝗽𝘀𝘁𝗮𝗻 𝗿𝗮𝗶𝘀𝗲𝘀 $𝟭𝟳𝟱𝗠 𝘁𝗼 𝘁𝗲𝘀𝘁 𝗶𝗻 𝘃𝗶𝘃𝗼 𝗖𝗔𝗥-𝗧 Laura Shawver pictures a world 10 years from now where cell therapies are replaced by in vivo CAR-T products. The goal is a cheaper-to-produce, less complex and more accessible cell therapy. Capstan Therapeutics, a biotechnology startup developing medicines that reprogram cells inside the body, has raised another $175 million to bring its first prospect into clinical testing. Capstan’s goal is to use messenger RNA technology to coax the body into making its own CAR-T cells. The high-profile startup, formed by a group of pioneering cell therapy and messenger RNA researchers, secured the financing from a wide range of investors led by RA Capital and including five pharmaceutical companies, it said Wednesday. Johnson & Johnson is one of Capstan’s new backers, joining existing investors Pfizer, Bristol Myers Squibb, Eli Lilly and Company and Bayer, among others. The startup has now raised $340 million since 2021.  Learn more : https://lnkd.in/eH6JKt8N #celltherapy #innovation

Alumis, an 𝐢𝐦𝐦𝐮𝐧𝐨𝐥𝐨𝐠𝐲 𝐛𝐢𝐨𝐭𝐞𝐜𝐡 on the cusp of 𝐏𝐡𝐚𝐬𝐞 𝟑, has secured $𝟐𝟓𝟎𝐌 𝐢𝐧 𝐚 𝐬𝐡𝐫𝐮𝐧𝐤𝐞𝐧 𝐈𝐏𝐎. The Bay Area startup sold 𝟏𝟑.𝟏𝟐 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 𝐬𝐡𝐚𝐫𝐞𝐬 𝐚𝐭 $𝟏𝟔 𝐞𝐚𝐜𝐡 to fund the late-stage testing of its lead 𝐓𝐘𝐊𝟐 𝐝𝐫𝐮𝐠, studies of a second asset in neuroinflammatory conditions, and preclinical projects. While the IPO was smaller than initially projected, an additional 𝟐.𝟓 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 𝐬𝐡𝐚𝐫𝐞𝐬 were sold in a concurrent private placement. With $𝟑𝟒𝟓 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 𝐚𝐥𝐥𝐨𝐜𝐚𝐭𝐞𝐝 toward clinical development, Alumis aims to create a next-gen immunology treatment, facing competition from Bristol Myers Squibb’s Sotyktu and Takeda’s TAK-279. Alumis has spent heavily on R&D, with $𝟏𝟑𝟕 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 𝐥𝐚𝐬𝐭 𝐲𝐞𝐚𝐫 𝐚𝐧𝐝 $𝟏𝟎𝟏 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 𝐢𝐧 𝟐𝟎𝟐𝟐. The company, led by Martin Babler, hopes to buck the trend of biotechs trading below their IPO price. https://lnkd.in/eK_H6kda #Biotech #Immunology #IPO #Pharma #HealthcareInnovation

VC investors from China and Hong Kong have backed the first close of a $21 million Series B round for Cambridge-based Life Science company CN Bio . Beijing-based Bayland Capital 康君资本 and founding shareholder CN Innovations Holdings Ltd from Hong Kong are to invest $10m and $5.5m, respectively. Other serial backers have reinvested. https://lnkd.in/eWSmHU_s The new money will enable CN Bio to expand product development and scale the organisation across key global markets to meet increased demand for Organ-on-a-Chip (OOC) solutions. CN Bio is a leading provider of single- and multi-organ microphysiological systems. The global OOC market’s CAGR is estimated at 30.94 per cent. CN Bio is delivering an ambitious expansion strategy to meet the increasing demand for its PhysioMimix® OOC technology and research services – and to provide deeper, clinically-relevant insights into early-stage preclinical drug discovery in a wider range of application areas, whilst reducing reliance on animal models. Dr Paul Brooks, CEO at CN Bio, said: “We are seeing pivotal growth across our industry, whereby drug developers are increasingly recognising the potential of OOC technology to augment, supplement and optimise their workflows. “We have strategically positioned ourselves accordingly to respond to the market needs and are proud to have received recognition from our major shareholder, CN Innovations, and new institutional investors such as Bayland Capital, to drive this vision forward.” Yuexing Su, Founding Partner, Bayland Capital, commented: “OOC technology is an exciting market with compelling opportunity for growth. CN Bio has taken key steps to build a team with extensive industry expertise and robust networks across the industry, with a longstanding track record of success.” Charles Chong, Managing Director, CN Innovations, added: “We are encouraged by CN Bio’s ongoing success and, in particular, the team’s achievements over the past years, during which conditions have been difficult in the broader economy. “In this time, key milestones have been met, not just for the Company, but also the wider industry – including CN Bio providing critical human-relevant compound efficacy data to support the FDA’s approval for Inipharm’s Phase 1 clinical trial for metabolic liver disease. “We are pleased to be supporting CN Bio again as it looks ahead and strengthens its future growth plans, of which, expanding its product portfolio in markets that hold huge impact for the industry, such as metabolic disease modelling and toxicology, will be key.”

🚀 Funding Frenzy in Biopharma: 2023 OrbiMed Funding Dashboard Insights by Octavus Consulting The 2023 OrbiMed Funding Dashboard paints an exciting picture of the pharmaceutical and biotechnology funding landscape. Let's dive into the key highlights: 💰 $3.08B* Total Funding Across 38 Deals 💠 Largest funding rounds: Series B ($724M), Series A ($639.6M), Series C ($529M) 🏆 Top 3 Largest Fundings: 💠Caris Life Sciences Inc. ($400M) 💠Upstream Biosciences ($200M) 💠ADARx Pharmaceuticals Inc. ($200M) 🌍 Global Reach: Majority of Investments in the US 🗽(25 companies), followed by China, Israel, and other countries 🔬 Investment Focus Areas: Oncology, Neurology, Hematology, Infectious Disease 🧬 Stage of Investment: 👉 Platform & Own Product Development (15 companies) 👉 Early R&D (11 companies) 👉 Late Stage Development & Commercialization (6 companies) 👉 Rare/Orphan Specialization (4 companies) 1 🔑 Key Takeaways: ▶ Biopharma funding remains robust, with significant investments in cutting-edge therapies and platform technologies ▶Global investors are actively seeking opportunities across the healthcare innovation ecosystem ▶Oncology, neurology, and infectious diseases continue to attract substantial funding Feel free to reach us at bd@octavusconsulting.com for any bespoke funding and data analysis #BiopharmaFunding #HealthcareInnovation #VentureCapital #MedicalResearch #Biotech #Pharma